Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Repeated Rhenium-188 HEDP plus Docetaxel versus Docetaxel alone in castration-resistant prostate cancer metastatic to bone
2009-018044-18Phase 2Active
- Sponsor
- Meander Medical Center
- Start
- Aug 2011
- Modality
- Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised trial in castration-resistant prostate cancer (CRPC) comparing Docetaxel alone with Docetaxel plus Rhenium-188-HEDP (2 arms). Primary endpoints: Time to progression and Safety. Started Aug 2011; status: active.
02
Drugs
docetaxelRhenium-188-HEDP
03
Conditions
castration-resistant prostate cancer (CRPC)
Beyond the preview
Go deeper on 2009-018044-18.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2009-018044-18.